Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study
The Lancet Neurology, 10/15/09
Urbanus RT et al. – Arterial thrombosis is a major clinical manifestation of the antiphospholipid syndrome, which is an autoimmune disease found mostly in young women. Although the presence of circulating antiphospholipid antibodies in individuals who have a thrombotic event is a prerequisite for the diagnosis of the antiphospholipid syndrome, the risk of arterial thrombosis associated with antiphospholipid antibodies in the general population is unclear.Our results suggest that lupus anticoagulant is a major risk factor for arterial thrombotic events in young women, and the presence of other cardiovascular risk factors increases the risk even further.
Methods- RATIO (Risk of Arterial Thrombosis In relation to Oral contraceptives), a large multicentre population-based case-control study
- Women aged under 50 years who were admitted to hospital at 16 centres with first ischaemic stroke or myocardial infarction between January, 1990, and October enrolled
- Additional 59 women who presented with ischaemic stroke at University Medical Centre Utrecht between 1996 and 2001 also enrolled
- Information on cardiovascular risk factors (such as oral contraceptive use, smoking, and hypertension) assessed with standard questionnaire
- During the second phase (1998—2002), blood samples taken to measure antiphospholipid antibody profiles (lupus anticoagulant, anticardiolipin IgG, anti-?2-glycoprotein I IgG, and antiprothrombin IgG) and determine genetic prothrombotic risk factors (factor V G1691A variant, prothrombin G20210A variant, and factor XIII 204Phe allele)
- 175 patients with ischaemic stroke, 203 patients with myocardial infarction, and 628 healthy controls included
- Lupus anticoagulant found in 30 (17%) patients with ischaemic stroke, 6 (3%) patients with myocardial infarction, and 4 (0·7%) in control group
- Odds ratio for MI 5·3 (95% CI 1·4—20·8), which increased to 21·6 (1·9—242·0) in oral contraceptive users and 33·7 (6·0—189·0) in smokers
- Odds ratio for ischaemic stroke 43·1 (12·2—152·0), which increased to 201·0 (22·1—1828·0) in oral contraceptive users and 87·0 (14·5—523·0) in smokers
- In women who had anti-?2-glycoprotein I antibodies, risk of ischaemic stroke 2·3 (1·4—3·7), but risk of MI not increased (0·9, 0·5—1·6)
- Neither anticardiolipin nor antiprothrombin antibodies affected risk of MI or ischaemic stroke
Today in Autoimmune/Heritable...keeping you current
Receive free subspecialty "5-minute updates" via email
Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity
Rheumatology, 11/20/09
T Cell Responses to Steroid Cytochrome P450 21-Hydroxylase in Patients with Autoimmune Primary Adrenal Insufficiency
Journal of Clinical Endocrinology and Metabolism, 11/20/09
Raised concentration of soluble form of vascular endothelial cadherin and IL-23 in sera of patients with Behçets disease
Modern Rheumatology, 11/19/09
Sponsor
Article Search
Sponsor


See Latest Articles


